Abstract:BACKGROUND:DeltaDNMT3B (a new DNMT3B subfamily) expression is initiated through a novel promoter. We identified at least 7 transcription variants of deltaDNMT3B as a result of alternative pre-mRNA processing. The aim of this study was to detect the expression pattern of deltaDNMT3B variants in non-small cell lung cancer (NSCLC) and to explore the role of deltaDNMT3B variants in regulating the promoter-specific DNA methylation.METHODS:Specific polymerase chain reaction (PCR) primer sets were designed to distinguish individual deltaDNMT3B variants according to their splicing patterns. The expressions of seven deltaDNMT3B variants were measured in 13 cell lines, 109 NSCLC patients, and the corresponding normal lung tissues using reverse transcription-PCR (RT-PCR). The status of the p16 and RASSF1A promoter methylations in the tumors was detected using a methylation specific PCR (MSP). The relationships of the expression patterns of the deltaDNMT3B variants were analyzed by observing the status of p16 and RASSF1A promoter methylations in the tumors. The siRNA and the anti-sense oligo-dioxynucleotide specifically targeting the junction of exon 5 and 7 of deltaDNMT3B were designed and transfected by lipofectmane 2000 into H1299 and H358 cell lines. RASSF1A promoter methylation from cells treated by siRNA-deltaDNMT3B4/2 was detected using MSP and Bisulfite sequencing, and Western blotting was used to detect the protein expression of DNMT3B and ADNMT3B. Cell growth and cell cycle distribution were measured by applying real-time cell growth analysis and flowcytometry, respectively.RESULTS:ADNMT3B variants, not DNMT3B, were the predominant transcripts in both NSCLC cell lines and primary tumors. The expression of deltaDNMT3B4 strongly correlated to the promoter methylation status of RASSF1A in a primary NSCLC. The knockdown of deltaDNMT3B4/2 by RNA-interference or anti-sense approaches resulted in a complete demethylation of RASSF1A promoter with the reactivation of a RASSF1A gene expression in less than 12 hours, but no effect resulted from the p16(INK4a) promoter in the NSCLC cell lines.CONCLUSIONS:These results demonstrate an important role of deltaDNMT3B4/2 in the maintenance of promoter-specific DNA methylation in a cell type specific manner and provide a novel cell model for the study of the regulation of replication-independent DNA methylation.

Detection of DNMT3b and HDAC1 binding to SLC22A18 gene promoter by optimised chromatin immunoprecipitation

The effects of 5-Aza-2-deoxycytidine, a methylation inhibitor, on the proliferation of androgen-sensitive prostate cancer cell line, and on the regulation of methylation of glutathione s-transferase P1 and retinoic acid receptorβ2 gene

[SHP-1 Gene's Methylation Status of Daudi Lymphoma Cell and the Demethylation Effect of 5-Aza-2'-deoxycytidine].

Progress in combined treatments of myelodysplastic syndrome and acute myeloid leukemia based on DNA methyltransferase inhibitors

Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

An Improved Method for Identifying Specific DNA-Protein-Binding Sites in Vitro.

[DNA methylation of HDAC4 gene affects the trans-differentiation process of hMSCs into sweat gland like cells]

Critical Role of Delta Dnmt3b4/2 in Regulating Rassf1a Promoter-Specific Dna Methylation in Non-Small Cell Lung Cancer

Insight into the Selective Binding Mechanism of DNMT1 and DNMT3A Inhibitors: a Molecular Simulation Study.

Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression.

A high sensitivity strategy of DNMT1 activity detection based on self-assembled nucleic acid probe signal amplification technique

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC-7721

Promoter methylation assay of SASH1 gene in breast cancer

Immunofluorescence Imaging Strategy for Evaluation of the Accessibility of DNA 5-Hydroxymethylcytosine in Chromatins

Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer

The Study on Chemical Suppression of Proliferation of MDA-MB-435 Through AZA and TSA

Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors

Development of a Versatile DNMT and HDAC Inhibitor C02S Modulating Multiple Cancer Hallmarks for Breast Cancer Therapy.

HDAC Inhibitors Act with 5-Aza-2'-deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells.

Development of a method for methylated DNA enrichment with functionalized mesocellular silica foams immobilized with methyl CpG binding domain